Skip to content
Open access · CC-BY via OpenAlex

Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age

Steven Ron Cummings, Stephen B. Kritchevsky

GeroScience · 2022 · ▲ 45 citations

Abstract

Treatments that target fundamental processes of aging are expected to delay several aging-related conditions simultaneously. Testing the efficacy of these treatments for potential anti-aging benefits will require clinical trials with endpoints that reflect the potential benefits of slowing processes of aging. There are several potential types of endpoints to capture the benefits of slowing a process of aging, and a consensus is needed to standardize and compare the results of these trials and to guide the analysis of observational data to support trial planning. Using biomarkers instead of clinical outcomes would substantially reduce the size and the duration of clinical trials. This requires validation of surrogate markers showing that treatment induced change in the marker reliably predicts the magnitude of change in the clinical outcome. The surrogate marker must also reflect the biological mechanism for the effect of treatment on the clinical outcome. "Biological age" is a superficially attractive marker for such trials. However, it is essential to establish that treatment induced change in biological age reliably predict the magnitude of benefits in the clinical outcome. Reaching consensus on clinical outcomes for geroscience trials and then validating potential surrogate biomarkers requires time, effort, and coordination that will be worthwhile to develop surrogate outcomes that can be trusted to efficiently test the value of many anti-aging treatments under development.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1007/s11357-022-00671-8
Canonical
link ↗
Fetched
2026-10-23 MST

Cite this

APA
Cummings, S.R., &amp; Kritchevsky, S.B. (2022). Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age. <em>GeroScience</em>. https://doi.org/10.1007/s11357-022-00671-8
Vancouver
Cummings SR, Kritchevsky SB. Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age. GeroScience. 2022. doi:10.1007/s11357-022-00671-8.
BibTeX
@article{steven2022Endpoi, title = {Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age}, author = {Steven Ron Cummings and Stephen B. Kritchevsky}, journal = {GeroScience}, year = {2022}, doi = {10.1007/s11357-022-00671-8}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings